Silo Pharma

Silo Pharma Inc. offers email alerts with company information and investor alerts.

Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company focused on underserved conditions, including stress-induced psychiatric disorders, chronic pain, and CNS diseases.

The policy describes how personal information is collected, used, communicated, and disclosed.

The page states that website use is subject to its Terms and Conditions of Use and applicable laws and regulations.

Silo Pharma enhances its QwikAgents platform by integrating **NVIDIA Nemotron models** and introducing the **Hermes runtime**, broadening options for AI models and agent software. The updates aim to provide customers with greater flexibility in deployment and execution. The company continues to strengthen its AI infrastructure for pharmaceutical and life sciences applications.

Sep 2026GlobeNewswireNews article

Silo Pharma secures a U.S. patent allowance for **SPC-15**, a treatment targeting PTSD. The approval strengthens the company’s intellectual property portfolio, supporting future development of its psychiatric therapies. The patent covers a novel compound under evaluation for PTSD management.

Sep 2026GlobeNewswireNews article

Silo Pharma presents its patented nose-to-brain drug delivery technology designed to treat PTSD at the 2026 Nasal Innovation Forum. The company specializes in biopharmaceutical innovations targeting neurological conditions via nasal administration. This technology aims to improve treatment efficacy by delivering drugs directly to the brain through nasal pathways.

Sep 2026GlobeNewswireNews article

Silo Pharma secures a private placement offering up to **$11.7 million** in gross proceeds, structured with **$4 million upfront** and an additional **$7.7 million** contingent on full warrant exercise. The transaction follows Nasdaq at-the-market rules, allowing flexibility in pricing and execution. The company leverages this financing to support operational growth and potential expansion of its pharmaceutical pipeline.

Jul 2026GlobeNewswireNews article